Cyclical breast pain — the tenderness that rises and falls with the menstrual cycle — is one of the most common reasons women visit a breast clinic, and one of the least satisfactorily treated. Hormonal drugs help some women and not others; painkillers take the edge off without addressing the pattern; and many women are simply told to live with it. That is the background against which a new trial deserves attention — not because it settles the question, but because of how it was designed.
A multicenter randomized trial published in BMC Complementary Medicine and Therapies on October 1, 2026, tested manual acupuncture against a sham procedure in 108 women with cyclical breast pain, known clinically as cyclic mastalgia. Its headline result is striking: the benefit was still there six months after treatment ended. But the real value of this study for readers is what it teaches about reading acupuncture evidence — where a sham control helps, where it cannot, and how much weight one trial can carry.
What They Did
The trial enrolled adult women with cyclic mastalgia at three outpatient centers in China and randomized them 1:1 to manual acupuncture or sham acupuncture. Both groups received the same schedule: 18 sessions over 12 weeks. That matching matters more than it may sound. In hands-on therapies, simply showing up, being attended to, and going through a treatment ritual can itself reduce symptoms. By giving both groups the same number of visits and the same treatment ritual, the investigators tried to isolate the effect of needling at defined points from the effect of being cared for.
The trial was registered prospectively on ClinicalTrials.gov (NCT05408377), and the primary outcome was the change in breast-pain score — measured on a standard visual analogue scale for breast pain (VAS-BP) — from baseline to week 12. Secondary outcomes included the proportion of women who responded to treatment, the number of days with breast pain, and quality of life measured with the World Health Organization's WHOQOL-BREF questionnaire. Follow-up continued to week 36, a full 24 weeks after the last session. Of the 108 women enrolled, 94 (87.0%) completed the trial, and the main analysis included all 108 randomized participants, following the intention-to-treat principle — that is, women counted in the group they were assigned to whether or not they finished every session.
What They Found
At week 12, the manual acupuncture group reported substantially less breast pain than the sham group: a between-group difference of −2.0 points on the pain scale, with a 95% confidence interval of −2.5 to −1.4. The interval sits well away from zero, so this is a clear separation, not a borderline result.
What makes the study unusual is what happened next. At week 36, twenty-four weeks after treatment had ended, the difference was −2.2 points (95% CI, −2.8 to −1.6). The benefit had not faded — if anything, it had deepened slightly. The number of days with breast pain fell by 2.0 more days in the acupuncture group at week 12 and by 3.0 more days at week 36. Quality of life improved more as well, with a total WHOQOL-BREF advantage of 13.5 points (95% CI, 5.1 to 21.7).
Perhaps the most vivid figure is the response rate. At week 12, 72.2% of women in the manual acupuncture group (39 of 54) were classified as responders, compared with just 22.2% (12 of 54) in the sham group. A threefold gap in response rates between an active treatment and a matched sham control is a large effect by the standards of pain research.
Safety was reassuring in this small sample: three mild adverse events were reported in the manual acupuncture group and none in the sham group, consistent with the generally favorable safety profile of acupuncture when performed by trained practitioners.
Why the Sham Control Matters — and Where It Stops
Acupuncture trials have a notorious control-group problem. A pill trial can use an identical-looking placebo; a needling trial cannot. Sham acupuncture typically mimics the sensory experience of treatment — needling at non-acupoint locations, or blunt needles that press without penetrating — so that participants cannot easily tell which group they are in. That is far stronger than a waiting-list comparison, where one group gets attention and ritual and the other gets nothing.
But sham control has structural limits that honest reporting should name. Practitioners cannot be blinded — the person holding the needle knows what they are doing — and participants may guess their assignment from sensations during treatment, such as the characteristic deqi feeling of soreness, numbness, or heaviness at the needle site. The large responder gap suggests the sham captured much of the ritual of care without reproducing the therapeutic effect, but it cannot fully exclude expectation effects. That is not a reason to dismiss the result; it is a reason to describe it precisely: this trial shows an effect beyond a matched sham procedure, under these conditions, in this population — not an effect proven free of all context.
The trial also leaves the mechanism open. Hormonal measures — estradiol, progesterone, and prolactin — were recorded among the study variables, and acupuncture research more broadly points to endogenous pain-modulatory pathways. But this study was not designed to prove how needling works, and a benefit that persists for six months after treatment raises as many questions as it answers. Durability is the finding most in need of replication, precisely because it is the most surprising.
What This Study Shows — and What It Cannot
Strengths. Prospective registration, a sham control matched for visit frequency and ritual, multicenter recruitment, an intention-to-treat analysis, and follow-up extending six months beyond treatment — this is the methodological template that complementary medicine trials need to meet if their results are to change clinical guidelines.
Limitations. First, the sample is modest: 108 participants is adequate for the primary endpoint but thin ground for subgroup claims or for generalizing broadly. Second, the trial was conducted entirely in China, where acupuncture is an established part of routine care; patient expectations — and therefore the size of any context effect — may differ in health systems where acupuncture is less familiar. Third, the study addressed cyclical mastalgia specifically. Non-cyclical breast pain has different underlying mechanisms and may respond differently, so these results should not be stretched to cover all breast pain. Fourth, this is a single trial. One well-designed study moves a question forward; it does not close it. Replication in other populations, and cost-effectiveness analysis, would be needed before acupuncture earns a place alongside analgesics and hormonal agents in treatment guidelines for this condition.
The Practical Reading
For a reader weighing whether to try acupuncture for cyclical breast pain, the honest summary is this: a 12-week course (18 sessions) produced a clinically noticeable reduction in pain that outlasted treatment by at least half a year in this trial, with measurable gains in quality of life and only mild side effects. That is cautiously encouraging — and it is also a result from one trial, in one country, in 108 women. It justifies a conversation with a qualified practitioner, not a guarantee.
One safety note belongs in any article on this topic, and it is not a footnote: new, persistent, one-sided, or otherwise unusual breast symptoms — a lump, nipple discharge, skin changes, or pain that does not follow your usual cycle — should be evaluated clinically first, before any complementary therapy is considered. Cyclical pain is common, but it is a description of a pattern, not a diagnosis to assign to yourself.
The deeper lesson is about evidence itself. For decades, acupuncture research has been stuck on the question "does it work?" — argued over control groups that were either too weak or too contested. This trial asks a more grown-up question and answers it with a stronger design: compared with a procedure designed to feel like treatment, does real needling do more, and does the difference last? On that question, for this condition, the answer this time was yes — durably, and by a margin worth noticing. The next question is whether other teams, in other places, find the same thing.
Source: Yu C, Shen B, Li X, Fang Y, Xu L, Han P, Wang X, Gao Y, Zhang Y, Guo J. "The long-term effects of acupuncture for cyclic mastalgia: a multicenter randomized clinical trial." BMC Complementary Medicine and Therapies. 2026. DOI: 10.1186/s12906-026-05622-w. Trial registration: NCT05408377.
If you are interested in how the classical Chinese medical tradition thinks about health more broadly — its ideas of balance, prevention, and the body's patterns — our book Huangdi Neijing: A Modern Introduction offers a beginner-friendly guide to the foundational text of TCM.
This article is for educational purposes only and is not medical advice. If you are experiencing breast pain, please consult a qualified healthcare professional.